New Longer-Term Safety Data of Chugai’s Satralizumab in Adults and Adolescents with Neuromyelitis Optica Spectrum Disorder Presented at EAN
2020-05-22 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, May 22, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release regarding the new longer-term safety data of satralizumab (development code: SA237) for the treatment of adults and adolescents with neuromyelitis optica spectrum disorder presented at the 6th Annual Meeting of the European Academy of Neurology. Satralizumab is an anti-IL-6 receptor recycling antibody created by Chugai. Please refer to the link below for details of the press release: New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder https://www.roche.com/media/releases/med-cor-2020-05-22.htm
The release as fetched from its publisher. chugai-pharm.co.jp ↗